Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study.
We aimed to verify safety and effectiveness of certoparin real-world use and to identify predictors of thromboembolic events or bleeding. This was a non-interventional study documenting patients at hospital- or office-based physicians. Patients' (n = 1407) mean age was 53.7 ± 16.1 years. Reason for certoparin use was prophylaxis of venous thromboembolism in 1331 (94.6%) patients and treatment in 76 (5.4%) patients. In only 11.4% of those receiving prophylaxis and 13.2% of those receiving treatment dosing, duration and schedule of certoparin were within label. There were 2 patients with deep venous thrombosis ([DVT], no pulmonary embolism [PE]), and 51 patients (3.8%) with minor (nonmajor) bleeding complications in patients receiving prophylaxis. Two patients treated with certoparin had recurrent DVT and one had PE (one patient with minor bleeding). Certoparin is very effective in real world. This also applies to patients in whom clinical decision making leads to an alteration of recommended application.